Poseida Therapeutics (PSTX)
(Delayed Data from NSDQ)
$2.07 USD
-0.09 (-4.17%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $2.06 -0.01 (-0.48%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PSTX 2.07 -0.09(-4.17%)
Will PSTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PSTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PSTX
Adaptimmune (ADAP) Down on End of Collaboration With Roche
Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue Estimates
PSTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Universal Health Services (UHS) Q4 Earnings and Revenues Top Estimates
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Misses Revenue Estimates
Poseida Therapeutics, Inc. (PSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for PSTX
Poseida Therapeutics management to meet with Piper Sandler
Analysts Are Bullish on Top Healthcare Stocks: Reviva Pharmaceuticals Holdings (RVPH), Roivant Sciences (ROIV)
Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE), Poseida Therapeutics (PSTX) and Align Tech (ALGN)
Poseida Therapeutics: A Strong Buy on Innovative Gene Therapy Advancements and Strategic Focus